Physician profile
Stuart M Barnes
NPI 1114106325
$3,562.06
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $34.41 · 2021: $717 · 2022: $1,014 · 2023: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $566.33 | 2019-2023 | Mounjaro, Trulicity, Emgality |
| Amgen INC. | $402.15 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $381.73 | 2019-2023 | Breztri |
| Novo Nordisk INC | $344.14 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $210.95 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $150.54 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.73 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $120.21 | 2019-2023 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $113.91 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Abbvie INC. | $110.99 | 2021-2023 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.61 | 2020-2023 | Stiolto Respimat |
| Dexcom, INC. | $101.30 | 2021-2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $96.62 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $93.16 | 2022 | |
| Merck Sharp & Dohme LLC | $88.81 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $88.55 | 2023 | Vyepti |
| Avanir Pharmaceuticals, INC. | $65.10 | 2019 | |
| Abbott Laboratories | $35.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $34.39 | 2023 | Ajovy |
| Sanofi-Aventis U.S. LLC | $32.56 | 2019-2023 | |
| Esperion Therapeutics, INC. | $32.03 | 2021 | |
| Allergan, INC. | $30.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2021 | |
| Clarus Therapeutics INC. | $25.29 | 2021 | |
| Astellas Pharma US INC | $24.49 | 2019 | |
| Antares Pharma, INC. | $19.55 | 2023 | Nocdurna, Tlando, Xyosted |
| Circassia INC. | $18.81 | 2019 | |
| Amneal Pharmaceuticals LLC | $18.32 | 2023 | Lyvispah |
| Halozyme INC | $17.43 | 2023 | |
| Xeris Pharmaceuticals, INC. | $17.00 | 2023 | Gvoke Hypopen |
| Insmed, INC. | $15.71 | 2022 | |
| Hikma Pharmaceuticals USA | $13.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.